StockNews.AI
OSTX
StockNews.AI
119 days

OS Therapies FDA Meeting Request Granted

1. OSTX secures FDA meeting to discuss breakthrough therapy designation for OST-HER2. 2. This could accelerate approval for treating lung metastatic osteosarcoma.

2m saved
Insight
Article

FAQ

Why Bullish?

The FDA's engagement signals potential successful therapy progress. Historical cases show breakthrough designations often positively impact stock prices.

How important is it?

The FDA's response is critical for OSTX's valuation and market confidence in clinical trials.

Why Short Term?

Immediate FDA discussions can lead to swift market reactions. Previous approvals in similar contexts have shown rapid stock movements.

Related Companies

EDITCRISAVCO
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food & Drug Administration (“FDA”) granted the Company's meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA.

Related News